Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 6Cancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesImmunotherapy and Immune Responses

The DOI matches its Crossref record; the references it cites are not checked yet.

Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges

Open access
Al-Hujaily, Ensaf M., Al-Sowayan, Batla S., Alyousef, Zeyad, Uddin, Shahab, Alammari, Farah·2022·International Journal of Molecular Sciences

Abstract

Cancer immunotherapies have changed the landscape of cancer management and improved the standard treatment protocols used in multiple tumors. This has led to significant improvements in progression-free survival and overall survival rates. In this review article, we provide an insight into the major immunotherapeutic methods that are currently under investigation for colorectal cancer (CRC) and their clinical implementations. We emphasize therapies that are based on monoclonal antibodies (mAbs) and adoptive cell therapy, their mechanisms of action, their advantages, and their potential in combination therapy. We also highlight the clinical trials that have demonstrated both the therapeutic efficacy and the toxicities associated with each method. In addition, we summarize emerging targets that are now being evaluated as potential interventions for CRC. Finally, we discuss current challenges and future direction for the cancer immunotherapy field.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms232213696

Cites

Statistics

Figures

Figure 1 One mAb antitumor mechanism of action is elucidated by directly targeting the host’s immune cells. This schematic illustration demonstrates how PD-1/PDL1 binds and blocks the effector T cell surface receptor that is responsible for immune checkpoint signaling. This halts tumor growth and results in an antitumor effect. PD1: anti-programmed death-1, PDL1: anti-programmed cell death ligand-1, TCR: T cell receptor, MHC-1: major histocompatibility complex-1, CTLA-4: anti-cytotoxic T-lymphocyte-associated antigen-4.
Figure 1 One mAb antitumor mechanism of action is elucidated by directly targeting the host’s immune cells. This schematic illustration demonstrates how PD-1/PDL1 binds and blocks the effector T cell surface receptor that is responsible for immune checkpoint signaling. This halts tumor growth and results in an antitumor effect. PD1: anti-programmed death-1, PDL1: anti-programmed cell death ligand-1, TCR: T cell receptor, MHC-1: major histocompatibility complex-1, CTLA-4: anti-cytotoxic T-lymphocyte-associated antigen-4.CC BY · PubMed Central
Figure 2 (A) Schematic illustration showing the variable light and heavy chains that are sequenced and combined into a single-chain variable fragment (scFv) to convert monoclonal antibody (mAb) to chimeric antigen receptor (CAR). (B) Schematic illustration showing the binding between the CAR-expressing immune effector cell and its tumor-associated antigen (TAA)-expressing tumor cell. This binding results in the production of cytotoxic granules and cytokines, which in turn causes stimulation of the host immune system and tumor cell death.
Figure 2 (A) Schematic illustration showing the variable light and heavy chains that are sequenced and combined into a single-chain variable fragment (scFv) to convert monoclonal antibody (mAb) to chimeric antigen receptor (CAR). (B) Schematic illustration showing the binding between the CAR-expressing immune effector cell and its tumor-associated antigen (TAA)-expressing tumor cell. This binding results in the production of cytotoxic granules and cytokines, which in turn causes stimulation of the host immune system and tumor cell death.CC BY · PubMed Central
Figure 3 Schematic illustration showing factors that contribute to the development of CRC pathogenesis. Mutation-induced CRC could be a result of new mutations or pre-existing mutations, specifically mutations in tumor suppressor genes and oncogenes. CRC: mutation-induced cancer, VEGF: vascular endothelial growth factor, EGFR: epidermal growth factor receptor.
Figure 3 Schematic illustration showing factors that contribute to the development of CRC pathogenesis. Mutation-induced CRC could be a result of new mutations or pre-existing mutations, specifically mutations in tumor suppressor genes and oncogenes. CRC: mutation-induced cancer, VEGF: vascular endothelial growth factor, EGFR: epidermal growth factor receptor.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

The citation lists are queued

They are fetched later and appear here then.

References 190 · Cited by 6

Metadata

Authors
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F.
Affiliations
  • King Saud bin Abdulaziz University for Health Sciences (SA)
  • Translational Research Institute and Dermatology Institute, Academic Health System, Hamad Medical Corporation, Doha 3050, Qatar
Corresponding author
Alammari, Farah
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-11-08
Volume
23
Issue
22
Pages
13696
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4308506941
Cited by
6
References
190
Citations by year
2026: 2 · 2025: 3 · 2023: 1
FWCI
0.12
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Keywords
colorectal cancer, cancer immunotherapy, monoclonal antibodies, adoptive immunotherapy, combination therapy, immunotherapy toxicity, clinical trials
MeSH terms
Antineoplastic Agents, Immunological, Antibodies, Monoclonal, Humans, Immunotherapy, Colorectal Neoplasms, Immunotherapy, Adoptive

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. https://app.cochat.ai/papers/10.3390/ijms232213696
The paper
Al-Hujaily, E. M., Al-Sowayan, B. S., Alyousef, Z., Uddin, S., & Alammari, F. (2022). Recruiting Immunity for the Fight against Colorectal Cancer: Current Status and Challenges. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms232213696

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.